Symptom scores remained stable over time, with similar QOL trends in both treatment arms.

People who live with chronic illness are expected to deal with their symptoms, brushing off their pain casually and hurting ...

An important unanswered question is whether rechallenging patients with enfortumab vedotin plus pembrolizumab after prior ICI exposure remains effective. The authors hypothesized that enfortumab ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Though some outcomes were also poorer with an interval less than a year, these were less clinically significant, experts say.

Using education and outreach to monitor beaches and promote sea turtle awareness and marine stewardship on St. John, US ...

"I am a women's health provider at a federally qualified health center and public hospital, and I've never been so scared for ...

Northwest Radon Poster Contest is underway, inviting students aged 9 to 14 from Idaho, Washington, and Oregon to create posters that raise awareness a ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held ...